BDR Pharmaceuticals International Private Ltd. is established in the year 2002 under able and dynamic leadership of our CMD Dharmesh Shah. BDR is involved in manufacturing of wide range of newer third generation API’s and also wide range of generic finished formulations. BDR’s core strength is identification of newer molecules, developing, commercializing and tie up worldwide. To meet with Global Competition and various qualification procedures worldwide, BDR is making significant investments in both R&D and their manufacturing facilities. Presently all BDR’s API manufacturing facilities are ISO 9002 and WHO GMP approved and are now building up Schedule M and Pharma Block for Europe and USA markets. BDR in their API range is focused on Non-Infringing Process, preparations of DMF’s as per ICH, US FDA Guidelines. BDR is also investing in up-gradation of its finished formulation facilities to get MCC South Africa, MHRA UK, TGA Australia and followed by USFDA approval. BDR is specialized in Lyophilized Injectables and Lyposomal Finished Formulations. BDR has widest range of Lyophilized Injectables and Lyposomal Finished Formulations. We at BDR offer solution for all Lyophilized Finished Formulations & also API’s. BDR has in year 2005 under taken representation of Delta Biotech in Argentina involved in manufacturing of Deltanoids, Anti-Glaucoma and Biotech Range of products. BDR is committed to have its strong and unique important position amongst giants in Global Competition and to share in best way has its own representative offices and agents world-wide. BDR in less than three years of its establishment has crossed turnover of USD 60 million as a group and is committed to maintain its significant position.
